ibuprofenamine (X-0002) / Techfields - LARVOL DELTA

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain (clinicaltrials.gov) - P3 | N=399 | Completed | Sponsor: Techfields Pharma Co. Ltd | Active, not recruiting ➔ Completed

Trial completion • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain (clinicaltrials.gov) - P3 | N=399 | Active, not recruiting | Sponsor: Techfields Pharma Co. Ltd | Trial primary completion date: May 2023 ➔ Jan 2024

Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Techfields Pharma Co. Ltd | N=750 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P3 | N=180 | Completed | Sponsor: Jiangsu XinChen-Techfields Pharma Co., LTD. | Active, not recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P3 | N=180 | Active, not recruiting | Sponsor: Jiangsu XinChen-Techfields Pharma Co., LTD. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2022 ➔ Dec 2022

Enrollment closed • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain (clinicaltrials.gov) - P3 | N=399 | Active, not recruiting | Sponsor: Techfields Pharma Co. Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain (clinicaltrials.gov) - P3 | N=408 | Recruiting | Sponsor: Techfields Pharma Co. Ltd | Trial completion date: Jul 2023 ➔ Jan 2024

Trial completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine (clinicaltrials.gov) - P3 | N=750 | Not yet recruiting | Sponsor: Techfields Pharma Co. Ltd | Trial completion date: Mar 2022 ➔ May 2025 | Trial primary completion date: Dec 2021 ➔ May 2024

Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Jiangsu XinChen-Techfields Pharma Co., LTD. | Phase classification: P2/3 ➔ P3

Phase classification • Immunology • Osteoarthritis • Pain • Rheumatology

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P2/3 | N=180 | Recruiting | Sponsor: Jiangsu XinChen-Techfields Pharma Co., LTD.

New P2/3 trial • Immunology • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain (clinicaltrials.gov) - P3; N=408; Recruiting; Sponsor: Techfields Pharma Co. Ltd; Not yet recruiting ➔ Recruiting; Trial completion date: Jun 2022 ➔ Jul 2023; Trial primary completion date: Dec 2021 ➔ Jan 2023

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Knee (clinicaltrials.gov) - P3; N=410; Not yet recruiting; Sponsor: Techfields Pharma Co. Ltd; N=600 ➔ 410

Enrollment change • Immunology • Osteoarthritis • Pain • Rheumatology

Safety, Tolerability, and Pharmacokinetics of Ibuprofenamine Hydrochloride Spray (NSAIDs), a New Drug for Rheumatoid Arthritis and Osteoarthritis, in Healthy Chinese Subjects. (PubMed, Drug Des Devel Ther) - "Single or multiple doses of ibuprofenamine hydrochloride were generally well tolerated and no obvious skin irritation was observed. Ibuprofenamine hydrochloride exhibited a safety and pharmacokinetic profile that supports its future investigation as a potential therapeutic for Rheumatoid Arthritis and Osteoarthritis."

Clinical • Journal • PK/PD data • Immunology • Osteoarthritis • Pain • Rheumatoid Arthritis • Rheumatology

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine (clinicaltrials.gov) - P3; N=750; Not yet recruiting; Sponsor: Techfields Pharma Co. Ltd; Trial completion date: Mar 2020 ➔ Mar 2022; Trial primary completion date: Dec 2019 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Knee (clinicaltrials.gov) - P3; N=600; Not yet recruiting; Sponsor: Techfields Pharma Co. Ltd; Trial completion date: Jun 2020 ➔ Jun 2022; Trial primary completion date: Dec 2019 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P2; N=360; Recruiting; Sponsor: Tianjin XinChen-Techfields Pharma Co., LTD.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open